Molluscum Contagiosum Clinical Trial
Official title:
Multicenter National Observational and Prospective Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
Molutrex® a 5% potassium hydroxide solution for topical application to the skin. Molutrex® is intended for the superficial treatment of certain types of warts, molluscum contagiosum and is composed of potassium hydroxide (5%) purified water. With regard to the 2017/745 RDM, he is a class IIa medical device. In accordance with Regulation (EU) 2017/745 of the European Parliament and of the Council of April 5, 2017 relating to medical devices, as part of the Molutrex® Post-Marketing Monitoring Plan, the objective of this study is to have data on the performance , safety and suitability for real-life use of Molutrex® in a prospective cohort of patients with molluscum contagiosum. Since molluscum contagiosum is most prevalent in children, and potassium hydroxide is used very little in adults (because most often they are immunocompromised patients requiring other antiviral treatments), the study will be conducted in children aged 2 to 10 years. This population represents the majority of patients treated with Molutrex®, although the product can be used in adults. The study includes 2 visits, the objective of the study being to evaluate the percentage of children healed at 45 days, healing defined by a reduction of more than 90% in the number of lesions present at inclusion in the study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03017846 -
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
|
Phase 2 | |
| Recruiting |
NCT05937672 -
Cold Atmospheric Plasma Device Extension Study
|
Phase 3 | |
| Completed |
NCT04535531 -
A Phase 3 Molluscum Contagiosum Efficacy and Safety Study
|
Phase 3 | |
| Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
| Completed |
NCT05897112 -
Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum
|
Phase 1 | |
| Withdrawn |
NCT05536882 -
MC RCT - BPO vs Adapalene
|
Phase 3 | |
| Completed |
NCT03377790 -
Cantharidin Application in Molluscum Patients-1
|
Phase 3 | |
| Completed |
NCT01348386 -
Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum
|
Phase 2/Phase 3 | |
| Completed |
NCT05634460 -
Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum
|
Phase 1 | |
| Completed |
NCT03186378 -
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
|
Phase 2 | |
| Completed |
NCT03927716 -
A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
|
Phase 3 | |
| Recruiting |
NCT04476186 -
The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children
|
N/A | |
| Completed |
NCT03927703 -
A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC
|
Phase 3 | |
| Completed |
NCT02665260 -
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
| Completed |
NCT03436615 -
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
|
Phase 2 | |
| Recruiting |
NCT02759900 -
Using a Cold Atmospheric Plasma Device to Treat Skin Disorders
|
N/A | |
| Completed |
NCT03077750 -
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
|
Phase 2 | |
| Terminated |
NCT02024581 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum
|
Phase 2 | |
| Completed |
NCT03377803 -
Cantharidin Application in Molluscum Patients
|
Phase 3 | |
| Withdrawn |
NCT03336372 -
Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients
|
Early Phase 1 |